Cadus Pharmaceutical Corp. (KDUS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS)

KDUS 1.600

0.0%

Jul 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tomato who wrote (463)	1/27/2001 11:23:43 PM
From: Mike McFarland	Read Replies (1) of 1833

recap.com Message 13711653 osip.com ............... GPCR DIRECTED OSI OWNED: (ADENOSINE RECEPTORS): - 1 target in IND track - Heart Disease - 3 targets in Lead Optimization - Asthma/Inflammation - Glaucoma OSI/SOLVAY FUNDED COLLABORATION WITH MILESTONES & ROYALTIES: - Parkinson's Disease - 1 target in IND track (licensed to Solvay with milestones & royalties) - multiple targets in Lead Seeking sec.gov more GPCR -- Directed Drug Discovery In August, 1999, OSI purchased certain assets of Cadus Pharmaceuticals Corporation. In this acquisition, OSI acquired Cadus' drug discovery programs focused on G-protein coupled receptors or GPCRs. These receptors are one of the most important families of targets for drug discovery in the pharmaceutical industry. Approximately, forty percent of the currently marketed pharmaceutical products target GPCRs. The acquired programs include Cadus' discovery program in adenosine receptors, an important family of GPCR's. These programs will form the core of OSI-owned and funded candidate development programs in the coming year.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next